Table 3 Difference in clinicopathological features due to age
Parameters | All intrinsic subtype (n = 191) | HR+HER2-BC (n =61) | HR+HER2+BC (n =27) | HER2BC (n =48) | TNBC (n =53) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Young (n =75) | Elderly (n = 116) | p value | Young (n =24) | Elderly (n = 39) | p value | Young (n =16) | Elderly (n = 11) | p value | Young (n =12) | Elderly (n = 36) | p value | Young (n =23) | Elderly (n = 30) | p value | |
Tumor size (mm) | |||||||||||||||
 ≤ 20.0 | 10 (13.3%) | 24 (20.7%) | 0.194 | 2 (8.3%) | 7 (17.9%) | 0.290 | 3 (18.8%) | 2 (18.2%) | 0.970 | 2 (16.7%) | 7 (19.4%) | 0.831 | 3 (13.0%) | 8 (26.7%) | 0.225 |
 > 20.0 | 65 (86.7%) | 92 (79.3%) | 22 (91.7%) | 32 (82.1%) | 13 (81.2%) | 9 (81.8%) | 10 (83.3%) | 29 (80.6%) | 20 (87.0%) | 22 (73.3%) | |||||
Skin infiltration | |||||||||||||||
 Negative | 68 (90.7%) | 90 (77.6%) | 0.020 | 20 (83.3%) | 29 (74.4%) | 0.405 | 14 (87.5%) | 6 (54.5%) | 0.055 | 12 (100.0%) | 29 (80.6%) | 0.098 | 22 (95.7%) | 26 (86.7%) | 0.267 |
 Positive | 7 (9.3%) | 26 (22.4%) | 4 (16.7%) | 10 (25.6%) | 2 (12.5%) | 5 (45.5%) | 0 (0.0%) | 7 (19.4%) | 1 (4.3%) | 4 (13.3%) | |||||
Lymph node status | |||||||||||||||
 Negative | 28 (37.3%) | 44 (37.9%) | 0.934 | 8 (33.3%) | 12 (30.8%) | 0.832 | 9 (56.2%) | 2 (18.2%) | 0.048 | 4 (33.3%) | 17 (47.2%) | 0.401 | 7 (30.4%) | 13 (43.3%) | 0.337 |
 Positive | 47 (62.7%) | 72 (62.1%) | 16 (66.7%) | 27 (69.2%) | 7 (43.8%) | 9 (81.8%) | 8 (66.7%) | 19 (52.8/%) | 16 (69.6%) | 17 (56.7%) | |||||
Estrogen receptor | |||||||||||||||
 Negative | 37 (49.3%) | 67 (57.8%) | 0.254 | 2 (8.3%) | 0 (0.0%) | 0.067 | 0 (0.0%) | 1 (9.1%) | 0.219 | – | – |  | – | – |  |
 Positive | 38 (50.7%) | 49 (42.2%) | 22 (91.7%) | 39 (100.0%) | 16 (100.0%) | 10 (90.9%) | – | – | – | – | |||||
Progesterone receptor | |||||||||||||||
 Negative | 42 (56.0%) | 89 (76.7%) | 0.003 | 5 (20.8%) | 16 (41.0%) | 0.099 | 2 (12.5%) | 7 (63.6%) | 0.006 | – | – |  | – | – |  |
 Positive | 33 (44.0%) | 27 (23.3%) | 19 (79.2%) | 23 (59.0%) | 14 (87.5%) | 4 (36.4%) | – | – |  | – | – | ||||
Hormone receptor- | |||||||||||||||
 Negative | 35 (46.7%) | 66 (56.9%) | 0.167 | – | – |  | – | – |  | – | – |  | – | – |  |
 Positive | 40 (53.3%) | 50 (43.1%) | – | – | – | – | – | – | – | – | |||||
HER2 | |||||||||||||||
 Negative | 47 (62.7%) | 69 (59.5%) | 0.660 | – | – |  | – | – |  | – | – |  | – | – |  |
 Positive | 28 (37.3%) | 47 (40.5%) | – | – | – | – | – | – | – | – | |||||
Ki67 | |||||||||||||||
 ≤ 14% | 22 (29.3%) | 40 (34.5%) | 0.458 | 12 (50.0%) | 21 (53.8%) | 0.767 | 7 (43.8%) | 2 (18.2%) | 0.166 | 1 (8.3%) | 12 (33.3%) | 0.091 | 2 (8.7%) | 5 (16.7%) | 0.396 |
 > 14% | 53 (70.7%) | 76 (65.5%) | 12 (50.0%) | 18 (46.2%) | 9 (56.2%) | 9 (81.8%) | 11 (91.7%) | 24 (66.7%) | 21 (91.3%) | 25 (83.3%) | |||||
ORR | |||||||||||||||
 Non-responders | 5 (6.7%) | 17 (14.8%) | 0.091 | 2 (8.3%) | 8 (20.5%) | 0.199 | 0 (0.0%) | 4 (36.4%) | 0.009 | 0 (0.0%) | 1 (2.8%) | 0.560 | 3 (13.0%) | 4 (13.3%) | 0.975 |
 Responders | 70 (93.3%) | 99 (85.2%) | 22 (91.7%) | 31 (79.5%) | 16 (100.0%) | 7 (63.6%) | 12 (100.0%) | 35 (97.2%) | 20 (87.0%) | 26 (86.7%) | |||||
Pathological response | |||||||||||||||
 Non-pCR | 46 (61.3%) | 78 (67.2%) | 0.403 | 18 (75.0%) | 37 (94.9%) | 0.021 | 13 (81.2%) | 10 (90.9%) | 0.488 | 1 (8.3%) | 14 (38.9%) | 0.048 | 14 (60.9%) | 17 (56.7%) | 0.758 |
 pCR | 29 (38.7%) | 38 (32.8%) | 6 (25.0%) | 2 (5.1%) | 3 (18.8%) | 1 (9.1%) | 11 (91.7%) | 22 (61.1%) | 9 (39.1%) | 13 (43.3%) | |||||
TILs | |||||||||||||||
 Low | 31 (41.3%) | 65 (56.0%) | 0.047 | 14 (58.3%) | 31 (79.5%) | 0.071 | 7 (43.8%) | 9 (81.8%) | 0.048 | 1 (8.3%) | 10 (27.8%) | 0.165 | 9 (39.1%) | 15 (50.0%) | 0.431 |
 High | 44 (58.7%) | 51 (44.0%) | 10 (41.7%) | 8 (20.5%) | 9 (56.2%) | 2 (18.2%) | 11 (91.7%) | 26 (72.2%) | 14 (60.9%) | 15 (50.0%) | |||||